ARCHIVES

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 18 | May 4, 2001

Download PDF Visit The Full Archive

Related Articles

Cancer Policy: President’s Cancer Panel Issues Statement On National Cancer Program

September 17, 1999

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

September 29, 2006

In Brief: Rall Says He’ll Return Money To NCI If There Isn’t Any Left; OMB Releases 28 Positions For NTP

February 1, 1980

IOM Panel Considering NCI Approach To Research In Minorities, Underserved

June 19, 1998

In Brief: Harkin Proposes To Add Another $400 Million To NCU Budget, Money To Come Forom Defense

July 26, 1991

After a “humble” start at NCI, von Eschenbach set unachievable goal.

September 30, 2005